Protective effect of aprepitant against chemotherapy-induced nausea and vomiting in postoperative chemotherapy for gastric cancer

Purpose: To investigate the clinical efficacy of aprepitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) caused by schemotherapy after gastric cancer surgery, and associated factors, as well as adverse reactions to the drug. Methods: A total of 100 postoperative gastric cancer patients in the Affiliated Cancer Hospital of Nanjing Medical University from January 2017 to January 2019, were randomly divided into control group (50 patients given dexamethasone + parlour SiQiong), and treatment group (50 patients given his minions horse temple + dexamethasone + parlour SiQiong). Recording of nausea and vomiting, as well as adverse reaction of patients, were started after 7 days of chemotherapy in patients. Results: The total effective control of acute CINV in the control group was 82 %, while the total effective control of acute CINV in the study group was 94 %. Values of total effective control of DFS in the control and study groups were 70 and 86 %, respectively. The incidence of adverse reactions was similar in the two groups. There was a significant correlation between the anti-emetic effect of aprepitant and gastric surgery. Conclusion: After gastric cancer surgery, combined treatment with aprepitant, palonosetron and dexamethasone prevents CINV induced by moderate emetogenic chemotherapy with orisaplatin. The combined treatment has good efficacy and can improve tolerance to, and compliance with chemotherapy.